Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) acquires, develops, and commercializes medically significant pharmaceutical products for the treatment of cancer and renal disease. It is currently developing Perifosine, “a novel, potentially first-in-class, oral anti-cancer drug candidate that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival.” Read more about Keryx Biopharmaceuticals' Perifosine. Given that most cancers are associated with high levels of activated Akt, and that Akt is often activated in tumors that resist other forms of anticancer therapy, the potential impact of this drug is far-reaching.
Keryx will be presenting Perifosine at the upcoming 53rd Annual Meeting of the American Society of Hematology (ASH), the largest professional society in the world that focuses on the causes and treatments of blood disorders. ASH aims to further “the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.” Read More
Dr. Paul Richardson, Clinical Director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute in Boston, MA will be presenting the final data results from Phase 1 / 2 Study of Perifosine + Bortezomib (VELCADE®) for the treatment of patients with relapsed and refractory Multiple Myeloma on Monday, December 12th. The conference will be held at the San Diego Convention Center in San Diego, California and will run from December 10 through 13, 2011.